Comments
Loading...

Regeneron Pharmaceuticals

REGNNASDAQ
Logo brought to you by Benzinga Data
$1138.81
-7.94-0.69%
At Close: -
$1146.75
7.940.70%
After Hours: 4:27 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$1300.00
Lowest Price Target1
$650.00
Consensus Price Target1
$1053.76

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock, Analyst Ratings, Price Targets, Forecasts

Regeneron Pharmaceuticals Inc has a consensus price target of $1053.76 based on the ratings of 31 analysts. The high is $1300 issued by Guggenheim on August 2, 2024. The low is $650 issued by B of A Securities on March 29, 2023. The 3 most-recent analyst ratings were released by RBC Capital, Cantor Fitzgerald, and Cantor Fitzgerald on September 17, 2024, September 16, 2024, and September 9, 2024, respectively. With an average price target of $1104 between RBC Capital, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied -3.73% downside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
May
4
Jun
3
1
Jul
5
Aug
3
2
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Cantor Fitzgerald
Piper Sandler
JP Morgan
Guggenheim

1calculated from analyst ratings

Analyst Ratings for Regeneron Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Regeneron Pharmaceuticals (REGN) stock?

A

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by RBC Capital on September 17, 2024. The analyst firm set a price target for $1282.00 expecting REGN to rise to within 12 months (a possible 11.79% upside). 59 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?

A

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by RBC Capital, and Regeneron Pharmaceuticals reiterated their outperform rating.

Q

When was the last upgrade for Regeneron Pharmaceuticals (REGN)?

A

The last upgrade for Regeneron Pharmaceuticals Inc happened on January 12, 2024 when RBC Capital raised their price target to $1076. RBC Capital previously had a sector perform for Regeneron Pharmaceuticals Inc.

Q

When was the last downgrade for Regeneron Pharmaceuticals (REGN)?

A

The last downgrade for Regeneron Pharmaceuticals Inc happened on June 28, 2023 when Canaccord Genuity changed their price target from $953 to $720 for Regeneron Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

Q

Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?

A

While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a reiterated with a price target of $1282.00 to $1282.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $1146.75, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch